X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20) 20
index medicus (20) 20
oncology (19) 19
female (14) 14
middle aged (14) 14
adult (12) 12
male (11) 11
aged (10) 10
cancer (9) 9
aged, 80 and over (6) 6
chemotherapy (6) 6
hematology, oncology and palliative medicine (6) 6
umcg approved (6) 6
care and treatment (5) 5
prognosis (5) 5
survival (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
efficacy (4) 4
health aspects (4) 4
medical research (4) 4
medicine, experimental (4) 4
metastasis (4) 4
netherlands (4) 4
safety (4) 4
analysis (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
breast-cancer (3) 3
cancer patients (3) 3
follow-up studies (3) 3
neoplasms - psychology (3) 3
ovarian cancer (3) 3
ovarian neoplasms - drug therapy (3) 3
patients (3) 3
pharmacology & pharmacy (3) 3
quality-of-life (3) 3
research (3) 3
risk (3) 3
risk factors (3) 3
surgery (3) 3
surveys and questionnaires (3) 3
tumors (3) 3
antineoplastic agents - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
association (2) 2
bevacizumab (2) 2
carboplatin - administration & dosage (2) 2
cisplatin (2) 2
clinical trial (2) 2
cyclophosphamide (2) 2
diagnosis (2) 2
disease (2) 2
disease-free survival (2) 2
disorders (2) 2
doxorubicin (2) 2
doxorubicin - administration & dosage (2) 2
drug therapy (2) 2
gastrointestinal stromal tumors - drug therapy (2) 2
geriatrics & gerontology (2) 2
gestational trophoblastic neoplasia (2) 2
hospital anxiety (2) 2
hypertension (2) 2
imatinib (2) 2
imatinib mesylate (2) 2
immunotherapy (2) 2
indoles - adverse effects (2) 2
internal medicine (2) 2
multicenter (2) 2
multivariate analysis (2) 2
neoplasm staging (2) 2
neoplasms - complications (2) 2
neoplasms - therapy (2) 2
obstetrics & gynecology (2) 2
obstetrics and gynecology (2) 2
polymorphism, single nucleotide - genetics (2) 2
predictive value of tests (2) 2
pregnancy (2) 2
prevalence (2) 2
progression (2) 2
psychological distress (2) 2
psychology (2) 2
psychology, multidisciplinary (2) 2
pyrroles - adverse effects (2) 2
quality of life - psychology (2) 2
renal-cell carcinoma (2) 2
sarcoma (2) 2
single nucleotide polymorphisms (2) 2
social sciences, biomedical (2) 2
stress, psychological - psychology (2) 2
survival rate (2) 2
targeted therapy (2) 2
treatment (2) 2
trial (2) 2
women (2) 2
1st-line sunitinib (1) 1
1st-line treatment (1) 1
abridged index medicus (1) 1
actinomycin-d (1) 1
activation (1) 1
adenocarcinoma, clear cell - blood (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 09/2018, Volume 69, pp. 233 - 242
The magnitude of clinical benefit scale (MCBS) was introduced by the European Society of Medical Oncology (ESMO) to quantify the clinical benefit of... 
Clinical benefit | Chemotherapy | ESMO-MCBS | Targeted therapy | Ovarian cancer | ADVANCED EPITHELIAL OVARIAN | INTRAVENOUS CISPLATIN PLUS | 1ST-LINE TREATMENT | RANDOMIZED-TRIAL | PHASE-III TRIAL | SINGLE-AGENT CARBOPLATIN | ONCOLOGY | TERM-FOLLOW-UP | CARBOPLATIN PLUS PACLITAXEL | INTRAPERITONEAL CISPLATIN | COOPERATIVE-ONCOLOGY-GROUP
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2015, Volume 26, Issue 10, pp. 2141 - 2149
The immune system is important in epithelial ovarian cancer (EOC). Interleukin-6 is associated with chemoresistance and an immune-suppressive tumor... 
Tumor immunity | Immunotherapy | Chemoresistance | Interleukin-6 | Ovarian cancer | Prognosis | Follow-Up Studies | Adenocarcinoma, Mucinous - pathology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Receptors, Interleukin-6 - antagonists & inhibitors | Cystadenocarcinoma, Serous - pathology | Adenocarcinoma, Clear Cell - blood | Cystadenocarcinoma, Serous - drug therapy | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Adenocarcinoma, Mucinous - blood | Interleukin-6 - blood | Doxorubicin - analogs & derivatives | Adult | Female | Adenocarcinoma, Mucinous - drug therapy | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Doxorubicin - administration & dosage | Cystadenocarcinoma, Serous - blood | CA-125 Antigen - blood | Enzyme-Linked Immunosorbent Assay | Neoplasm Invasiveness | Carboplatin - administration & dosage | Ovarian Neoplasms - blood | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Biomarkers, Tumor - blood | Interferon-alpha - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Adenocarcinoma, Clear Cell - pathology | Aged | Neoplasm Staging | Endometrial Neoplasms - blood | Interferon-gamma - blood | Adenocarcinoma, Clear Cell - drug therapy | Index Medicus
Journal Article
Nederlands Tijdschrift voor Geneeskunde, ISSN 0028-2162, 11/2006, Volume 150, Issue 47, pp. 2619 - 2620
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2014, Volume 25, Issue suppl_4, pp. iv501 - iv501
Abstract Aim: Caregiver support is vital for pts facing cancer treatment. Overstraining and distress may occur as a consequence, and can have serious... 
Journal Article
Journal Article
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 08/2016, Volume 158, Issue 3, pp. 563 - 572
To date, little is known about enduring clinical distress as measured with the commonly used distress thermometer. We therefore used the distress thermometer... 
Journal Article
European Journal of Surgical Oncology, ISSN 0748-7983, 03/2019, Volume 45, Issue 3, pp. 410 - 415
A cohort of 201 patients with small bowel gastrointestinal stromal tumors (GIST) treated between January 1st, 2009 and December 31st, 2016 in five GIST... 
GIST | Treatment | Sarcoma | Small bowel | Surgery | MULTICENTER | EFFICACY | SAFETY | PATHOLOGY | PHASE-II TRIAL | ONCOLOGY | DOSE IMATINIB | IMATINIB MESYLATE | Medical research | Care and treatment | Relapse | Analysis | Medicine, Experimental | Development and progression | Metastasis | Health aspects | Risk factors | Diseases
Journal Article
Nederlands Tijdschrift voor Dermatologie en Venereologie, ISSN 0925-8604, 2017, Volume 27, Issue 6, pp. 308 - 311
Journal Article
Acta Oncologica, ISSN 0284-186X, 02/2019, Volume 58, Issue 2, pp. 191 - 199
Background: TKIs are a long-term treatment for GIST, and may have an impact on caregivers. Material and Methods: For this cross-sectional study, patients and... 
SURVIVAL | FEAR | IMPACT | ONCOLOGY | IMATINIB | HOSPITAL ANXIETY | QUALITY-OF-LIFE | FAMILY CAREGIVERS | CANCER | PROGRESSION | PARTNERS
Journal Article
Breast, ISSN 0960-9776, 10/2016, Volume 29, pp. 1 - 7
Purpose: Patients with breast cancer may develop dental problems due to treatment. We examined the prevalence of their dental care use and needs, compared the... 
Journal Article
Journal Article